184 related articles for article (PubMed ID: 12594127)
1. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.
Licata G; Pinto A; Tuttolomondo A; Banco A; Ciccia F; Ferrante A; Triolo G
Ann Rheum Dis; 2003 Mar; 62(3):280-1. PubMed ID: 12594127
[No Abstract] [Full Text] [Related]
2. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behçet's disease.
Andonopoulos AP; Meimaris N; Daoussis D; Bounas A; Yiannopoulos G
Clin Exp Rheumatol; 2003; 21(4 Suppl 30):S57-8. PubMed ID: 14727465
[No Abstract] [Full Text] [Related]
3. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.
Goossens PH; Verburg RJ; Breedveld FC
Ann Rheum Dis; 2001 Jun; 60(6):637. PubMed ID: 11350856
[No Abstract] [Full Text] [Related]
4. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease.
Triolo G; Vadalà M; Accardo-Palumbo A; Ferrante A; Ciccia F; Giardina E; Citarrella P; Lodato G; Licata G
Ann Rheum Dis; 2002 Jun; 61(6):560-1. PubMed ID: 12006336
[No Abstract] [Full Text] [Related]
5. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.
Ju JH; Kwok SK; Seo SH; Yoon CH; Kim HY; Park SH
Clin Rheumatol; 2007 Aug; 26(8):1383-5. PubMed ID: 17039261
[TBL] [Abstract][Full Text] [Related]
6. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
7. Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
Sfikakis PP; Theodossiadis PG; Katsiari CG; Kaklamanis P; Markomichelakis NN
Lancet; 2001 Jul; 358(9278):295-6. PubMed ID: 11498218
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.
Fujikawa K; Aratake K; Kawakami A; Aramaki T; Iwanaga N; Izumi Y; Arima K; Kamachi M; Tamai M; Huang M; Nakamura H; Nishiura Y; Origuchi T; Ida H; Eguchi K
Ann Rheum Dis; 2007 Jan; 66(1):136-7. PubMed ID: 17178762
[No Abstract] [Full Text] [Related]
9. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
Sarwar H; McGrath H; Espinoza LR
J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
[TBL] [Abstract][Full Text] [Related]
10. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
[No Abstract] [Full Text] [Related]
11. Remission of Behçet's syndrome with TNFalpha blocking treatment.
Rozenbaum M; Rosner I; Portnoy E
Ann Rheum Dis; 2002 Mar; 61(3):283-4. PubMed ID: 11830448
[No Abstract] [Full Text] [Related]
12. [Spondylarthropathy with Behçet's disease: response to infliximab].
Toussirot E; Schwartz C; Hafsaoui C; Bossert M; Bertolini E; Wendling D
Presse Med; 2009; 38(7-8):1183-5. PubMed ID: 19395229
[No Abstract] [Full Text] [Related]
13. Infliximab in refractory uveitis due to Behçet's disease.
Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
[TBL] [Abstract][Full Text] [Related]
14. Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.
Pipitone N; Olivieri I; Padula A; D'angelo S; Nigro A; Zuccoli G; Boiardi L; Salvarani C
Arthritis Rheum; 2008 Feb; 59(2):285-90. PubMed ID: 18240181
[No Abstract] [Full Text] [Related]
15. Refractory primary central nervous system vasculitis of childhood: successful treatment with infliximab.
Batthish M; Banwell B; Laughlin S; Halliday W; Peschken C; Paras E; Benseler S
J Rheumatol; 2012 Nov; 39(11):2227-9. PubMed ID: 23118297
[No Abstract] [Full Text] [Related]
16. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.
Kram MT; May LD; Goodman S; Molinas S
Dis Colon Rectum; 2003 Jan; 46(1):118-21. PubMed ID: 12544532
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease.
Nakamura S; Ohno S
Int Ophthalmol Clin; 2005; 45(2):179-89. PubMed ID: 15791165
[No Abstract] [Full Text] [Related]
18. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients.
Lanthier N; Parc C; Scavennec R; Dhôte R; Brézin AP; Guillevin L
Presse Med; 2005 Jul; 34(13):916-8. PubMed ID: 16142147
[TBL] [Abstract][Full Text] [Related]
19. Behçet's disease: a new target for anti-tumour necrosis factor treatment.
Sfikakis PP
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii51-3. PubMed ID: 12379622
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of genital ulcers with infliximab in Behcet's disease.
Haugeberg G; Velken M; Johnsen V
Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
